Development · 15 Sep 2026

Aurobindo Pharma stated that the US Food and Drug Administration concluded its inspection of Unit-II, an active pharmaceutical ingredient manufacturing facility of its subsidiary Apitoria Pharma in Telangana, with one procedural observation.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

cnbctv18.com15 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Aurobindo Pharma

₹1,676.80

▲ +0.29%

Close (EOD), as of 1 Oct 2026 · source

Aurobindo Pharma: results, dividends, orders, the full cited record →

More on Aurobindo Pharma

US pharma tariff relief has different implications for Indian drugmakers depending on whether their US business is built around patented medicines, generics, complex injectables or contract manufacturing.

2 Oct 2026 · 1 publisher

Pharma stocks are picking up pace, with the sector continuing to show a strong overall technical setup despite the possibility of short-term profit booking.

2 Oct 2026 · 1 publisher

Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US - The HinduBusinessLine ... market and expands the company ... s commercial presence ... Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey in the U.S.

2 Oct 2026 · 2 publishers

Aurobindo Pharma announced that it has received final approval to manufacture and market beclomethasone dipropionate hfa inhalation aerosol in the US.

17 Sep 2026 · 5 publishers

Aurobindo Pharma's Pydibhimavaram, Andhra Pradesh-based API manufacturing facility has cleared a U.S. Food and Drug Administration (FDA) inspection with zero observations.

14 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.